Ayala Pharmaceuticals
(OTC) ADXS
Ayala Pharmaceuticals Financials at a Glance
Market Cap
N/A
Revenue (TTM)
$13.00K
Net Income (TTM)
$48.07M
EPS (TTM)
N/A
P/E Ratio
N/A
Dividend
N/A
Beta (Volatility)
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
ADXS News
ADXS: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Ayala Pharmaceuticals
Industry
Biotechnology
Sector
Health CareEmployees
15
CEO
Ken Berlin
Website
www.advaxis.comHeadquarters
Monmouth Junction, NJ 08852, US
ADXS Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
-2790%
Net Income Margin
-3698%
Return on Equity
122%
Return on Capital
4%
Return on Assets
-3%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Short Interest
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$0.00
Operating Income
$36.27M
EBITDA
$35.87M
Operating Cash Flow
$29.48M
Capital Expenditure
$0.00
Free Cash Flow
$29.48M
Cash & ST Invst.
$4.88M
Total Debt
$8.32M
Ayala Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
-100.0%
Gross Profit
$0.00
N/A
Gross Margin
0.00%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
20
N/A
Net Income
$24.67M
-157.3%
EBITDA
$8.53M
+12.0%
Quarterly Fundamentals
Net Cash
$3.43M
-622.7%
Accounts Receivable
$0.00
-100.0%
Inventory
$0.00
-100.0%
Long Term Debt
$8.15M
+511.9%
Short Term Debt
$166.00K
-60.4%
Return on Assets
-2.90%
N/A
Return on Invested Capital
4.30%
N/A
Free Cash Flow
$7.20M
+11.8%
Operating Cash Flow
$7.20M
+11.8%